nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: reception of allopurinol 300 mg (manufacturing Ramopharmin Pharmaceutical Company) once a day, for 4 months. Intervention 2: Control group: reception of placebo (ma
Treatment - Drugs
Placebo
Intervention group: reception of allopurinol 300 mg (manufacturing Ramopharmin Pharmaceutical Company) once a day, for 4 months
Control group: reception of placebo (manufacturing faculty of pharmacy) once a day, for 4 months
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 70 years Not having history of alcohol consumption Lack of other liver diseases The levels of aminotransferases should not exceed 2.5 times the upper limit of normal No previous allergy to allopurinol Not having chronic kidney disease (definedas an estimated glomerular filtration rate <60 mL/min/1.73m2) Serum uric acid levels greater than 4 mg/dl for men and more than 3 mg/dl for women For diabetic patients, hemoglobin A1c should be less than 8% and the dose of antidiabetic drugs should be constant for at least 3 months Not having hematological disorders Not having kidney stones
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Use of drugs interact with allopurinol (including didanosine, angiotensin-converting enzyme inhibitors, antacids (except sodium bicarbonate), azathioprine, mercaptopurine, vitamin K antagonists (including warfarin and other coumarin derivatives)) Taking hepatotoxic drugs (including calcium channel blockers, high doses of synthetic estrogens, methotrexate, amiodarone, chloroquine) Occurrence of allergic reaction due to allopurinol intake
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver steatosis. Timepoint: before the intervention and at the end of the study. Method of measurement: abdominal computed tomography scans-no contrast injection-spiral (liver hounsfield unit and the liver attenuation index (liver hounsfield unit minus spleen hounsfield unit)).;Change in systemic inflammation. Timepoint: before the intervention and at the end of the study. Method of measurement: high sensitivity c-reactive protein. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in insulin resistance. Timepoint: before the intervention and at the end of the study. Method of measurement: homeostasis model assessment of insulin resistance.;Change in oxidative stress. Timepoint: before the intervention and at the end of the study. Method of measurement: malondialdehyde.;Change in lipid profile. Timepoint: before the intervention and at the end of the study. Method of measurement: triglycerides, total cholesterol, high density lipoprotein, low density lipoprotein.;Change in liver enzymes. Timepoint: before the intervention and at the end of the study. Method of measurement: alanine aminotransferase, aspartate aminotransferase.;Change in anthropometric measurements. Timepoint: before the intervention and at the end of the study. Method of measurement: weight, body mass index, waist circumference, hip circumference, waist to hip ratio. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfshin Shiva
Oroumia University of Medical Sciences
Outcome results
None listed